Amdoxovir

Source: Wikipedia, the free encyclopedia.
Amdoxovir
Clinical data
ATC code
  • none
Identifiers
  • [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
JSmol)
  • n2c1c(nc(nc1n(c2)[C@@H]3O[C@@H](OC3)CO)N)N
  • InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1 checkY
  • Key:RLAHNGKRJJEIJL-RFZPGFLSSA-N checkY
  (verify)

Amdoxovir is a pharmaceutical drug that has undergone research for the treatment of

nucleoside reverse transcriptase inhibitor (NRTI). The drug was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia) and developed by RFS Pharma.[1]

Amdoxovir was in advanced

Phase II clinical trials around 2010.[2] In 2013, a Phase II trial was terminated[3] and another was withdrawn before it started.[4]
No further studies appear to have been done.

References

  1. ^ "Amdoxovir". AIDSmeds.com. January 13, 2009. Archived from the original on 2008-03-21. Retrieved March 21, 2008.
  2. PMID 20386073
    .
  3. ^ Clinical trial number NCT01737359 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT01738555 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov
drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Amdoxovir&oldid=1187850093"